London-based Boltz, which is developing AI models to speed up drug discovery, raised a $110M Series A led by Bessemer, after raising a $28M seed in 2025 (John Reynolds/Tech.eu)
Investors are continuing to direct significant capital toward computational biology platforms aimed at shortening pharmaceutical research timelines. By securing major venture backing, the biotechnology firm gains substantial resources to advance algorithms that streamline the identification of therapeutic candidates. The rapid progression in its capital structure reflects strong market confidence in software-driven approaches to laboratory science. Specifically, the company previously secured a $28 million seed round in 2025 prior to closing this latest growth round.
Key points
The startup has successfully closed a Series A investment totaling one hundred and ten mi…: The startup has successfully closed a Series A investment totaling one hundred and ten million dollars.
Funding will support the technological development of machine learning tools tailored for…: Funding will support the technological development of machine learning tools tailored for pharmaceutical research.
The London-headquartered firm is rapidly expanding its financial backing following its ea…: The London-headquartered firm is rapidly expanding its financial backing following its earlier 2025 seed capitalization.
Sources checked by our analysis pipeline: 1
Reuters: |
CNBC: |
New York Times: |
Jasmine Sun / New York Times: |
Financial Times: |
The Information: |
Koray Kavukcuoglu / Google: |
Abner Li / 9to5Google: |
Tim Bradshaw / Financial Times: |
Bill Toulas / BleepingComputer: |
Will Mathis / Bloomberg: |
Gerardo Fortuna / Politico: |
OpenAI: |
OpenAI: |
Jaspreet Singh / Reuters: |
New York Times: |
Todd Spangler / Variety: |
Jay Peters / The Verge: |
Joseph Bernstein / New York Times: |
Lynn Doan / Bloomberg: |
Aisha Malik / TechCrunch: |
Teresa Xie / Bloomberg: |
Yuan Gao / Bloomberg: |
Bloomberg: |
Dean Ball / OpenAI: |
Dana Goldstein / New York Times: |
Saritha Rai / Bloomberg: |
Christian Davies / Financial Times: |
New York Times: |
John Reynolds / Tech.eu: |
CoinDesk: |
Elena Eisenstadt / Bloomberg: |
This is a Techmeme archive page. It shows how the site appeared at 12:05 PM ET, November 19, 2026.
The most current version of the site as always is available at our home page. To view…
Domestic pharmaceutical innovation is turning toward advanced artificial intelligence while federal leaders focus on strategic global positioning against international competitors. Merck is deploying external machine learning tools to accelerate cancer therapies, even as key leadership transitions create regulatory uncertainty. The evolving intersection of cutting-edge technology and government oversight will determine the pace of modern drug development.
Strong investor demand fueled an immediate surge in equity value during the company's first public trading session. This milestone establishes a massive new public valuation benchmark for the broader artificial intelligence sector. The listing represents a critical moment as major foundational AI developers transition to public capital markets.
The London High Court defence tests whether artificial intelligence developers are responsible for the misuse and training architecture of their platforms. Legal representatives contend that obviously fictitious media does not infringe privacy rights, while the claimant argues designers cannot hide behind user prompts. The outcome could establish vital accountability standards as global regulators intensify scrutiny over non-consensual synthetic material.